^
Association details:
| Biomarker: | EGFR L858R + EGFR T790M |
|---|---|
| Cancer: | Lung Cancer |
| Drug: | Tagrisso (osimertinib) (EGFR inhibitor) + Zarnestra (tipifarnib) (CXCL12 inhibitor, Farnesyl transferase inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
LB080 / 5 - Tipifarnib prevents emergence of resistance to osimertinib in EGFR-mutant NSCLC
Published date:
03/09/2022
Excerpt:
Co-treatment with tipifarnib, a clinically active FTi, safely and durably prevented relapse to osimertinib in a PC9-xenograft model as well as in a PDX model of EGFR L858R/T790M lung cancer for up to 6 months with no evidence of toxicity.
